Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06439602
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-05-28
Brief Title:
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients
Sponsor:
Arthrosi Therapeutics
Organization:
Arthrosi Therapeutics
Study Overview
Official Title:
A Phase 3 Randomized Double-blind Multi-center Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None